Weight-loss drugs have been found to dramatically slash death rates in colon cancer patients, according to new research.
Patients taking GLP-1 receptors - the class of drugs behind Ozempic, Wegovy and Mounjaro - were less than half as likely to die within five years compared to those who weren’t on the drugs, scientists at the University of California San Diego said.
